Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19401232 | 0.94 | ACHE (0.50) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL20886684 | 0.92 | CA12 (0.46) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL12700650 | 0.92 | FFAR1 (0.40) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL8979037 | 0.91 | ALDH1A1 (0.57) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL19403106 | 0.89 | CA12 (0.41) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL8979134 | 0.88 | GRM5 (0.42) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL10018724 | 0.88 | GRM5 (0.42) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL7858588 | 0.88 | GRM5 (0.42) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL8978800 | 0.88 | FFAR1 (0.41) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL8978969 | 0.85 | FFAR1 (0.46) | KCNH2CYP2A6FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3529331-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-10711195-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-10662377-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2020-05-26 | — | — | US | disclosed |
| EP-3433337-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190330530-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190106626-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-04-11 | — | — | US | disclosed |
| US-20190100695-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-04-04 | — | — | US | disclosed |
| WO-2018077765-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017162717-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162716-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | WO | disclosed |
| EP-0581272-B1 | Tolane derivatives, liquid crystal compositions containing the derivatives and liquid crystal display device using the compositions | SEIKO EPSON CORP (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5356558-A | Compatibility, high speed response | SEIKO EPSON CORPORATION (JP) | 1994-10-18 | — | — | US | disclosed |
| EP-0581272-A1 | Tolane derivatives, liquid crystal compositions containing the derivatives and liquid crystal display device using the compositions | SEIKO EPSON CORPORATION (JP) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | FES, BLM, CXCL12 | GRM5 3822/4885CA12 213/4885CA2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.